Thiogenesis Therapeutics, Corp. News Releases

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.Meeting...

Thiogenesis Engages Brisco Capital for Investor Relations

Thu, 03 Sep 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services. Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to...

Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

Mon, 13 Jul 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome.The FDA grants...

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

Wed, 17 Jun 2026 08:00:00 -0400

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life...

Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million

Wed, 03 Jun 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of...

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Mon, 01 Jun 2026 14:49:00 -0400

San Diego, California--(Newsfile Corp. - June 1, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, today announced that, due to strong investor demand, it has increased the size of its previously announced non-brokered private placement (the "Offering") (see the Company's news release dated May 11, 2026) from 16 million to approximately...

Thiogenesis Announces Non-Brokered Private Placement

Mon, 11 May 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - May 11, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, announced today that it will undertake a non-brokered private placement (the "Offering") of up to 16,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share for gross proceeds of $8 million.This Offering is subject to...

Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference

Thu, 16 Apr 2026 09:00:00 -0400

San Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto, Canada.Presentation Details:Date: Wednesday, April 22, 2026Time:...

Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Mon, 02 Feb 2026 09:00:00 -0500

San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University...

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Fri, 23 Jan 2026 09:00:00 -0500

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improvement San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients...